Products
Ledostomig Biosimilar Bispecific Antibody (CD73 × PD-1) for Research
Cat No.: GMP-Bios-INN-1255
Anti-NT5E/CALJA/CD73 therapeutic antibody (Pre-made Ledostomig biosimilar,Bispecific Mixed mAb and scFv) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Ledostomig is a bispecific antibody targeting CD73 (NT5E) and PD-1 (PDCD1). It is in early-stage development for solid tumors. Further development details are under investigation.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1255-1mg | 1mg | |
| GMP-Bios-INN-1255-10mg | 10mg | |
| GMP-Bios-INN-1255-100mg | 100mg | |
| GMP-Bios-INN-1255-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Ledostomig biosimilar, Bispecific Mixed mAb and scFv, Anti-NT5E/CALJA/CD73;PDCD1/CD279/PD1 Antibody: Anti-CD73/NT5E/5'-nucleotidase/5'-NT therapeutic antibody |
| INN Name | Ledostomig |
| Target | NT5E/CALJA/CD73;PDCD1/CD279/PD1 |
| Format | Bispecific Mixed mAb and scFv |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1;na |
| VD LC | Kappa;Kappa |
| Highest_Clin_Trial (Jan '20) | TBC |
| Est. Status | TBC |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2025 |
| Year Recommended | na |
| Companies | TBC |
| Conditions Approved | TBC |
| Conditions Active | TBC |
| Conditions Discontinued | TBC |
| Production | na |
| Development Tech | TBC |
